Results 111 to 120 of about 379 (143)

Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin

Clinical Neuropharmacology, 2022
Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe.
Ozge Gonul Oner, Hasan Can Gudek, Ozdem Erturk Cetin, Serkan Demir   +3 more
openaire   +2 more sources

Antitoxin therapy for botulinum intoxication

Reviews in Medical Microbiology, 2001
Botulinum toxin is the most toxic substance known to mankind. It is involved in infant botulism, classical food-borne botulism, wound botulism, and is a threat in biological warfare or bioterrorism.
Carl N. Mayers, Jane L. Holley, Tim Brooks   +2 more
openaire   +1 more source

A review of WHO International Standards for botulinum antitoxins

Biologicals, 2006
Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on
R G A, Jones, M J, Corbel, D, Sesardic
openaire   +2 more sources

Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin

Toxicon, 2001
The neutralization of botulinum toxin serotype A with polyclonal equine antitoxin was studied in isolated mouse hemidiaphragms and compared to the same action in live mice. The biological activity of the toxin in the isolated muscle could be markedly reduced with excess antitoxin, estimated as 3:1 molar ratios of IgG Ab:toxin or better.
R E, Sheridan, S S, Deshpande, P, Amersdorfer, J D, Marks, T, Smith   +4 more
openaire   +2 more sources

An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins

Vaccine, 2017
Botulism therapy relies on passive immunization with antitoxin. The mouse neutralization test is the only pharmacopeia assay to measure the potency of antitoxin preparations. Herein, we present an in vitro cell-based assay for the measurement of pharmaceutical type A antitoxin potency. Accuracy, reproducibility and compatibility with the mouse bioassay
Amram, Torgeman, Eran, Diamant, Lilach, Levin, Alon Ben, David, Eyal, Epstein, Meni, Girshengorn, Ohad, Mazor, Ronit, Rosenfeld, Ran, Zichel   +8 more
openaire   +2 more sources

Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F

Clinical Immunology, 2010
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Yun-Zhou, Yu, Shu-Ming, Zhang, Yao, Ma, Heng-Qi, Zhu, Wen-Bing, Wang, Yun, Du, Xiao-Wei, Zhou, Rui-Lin, Wang, Shuang, Wang, Wei-Yuan, Yu, Pei-Tang, Huang, Zhi-Wei, Sun   +11 more
openaire   +2 more sources

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan

Toxicon, 2016
Japanese botulinum antitoxins have been used for more than 50 years; however, their safety and therapeutic efficacy are not clear. In order to analyze the available data on botulinum antitoxin therapy in Japan, we surveyed published reports about botulism cases in which botulinum antitoxins were used, and retrospectively analyzed the safety and ...
Keita, Mottate, Hiroyuki, Yokote, Shigemi, Mori, Akira, Horita, Yoshinobu, Miyatsu, Yasushi, Torii, Shunji, Kozaki, Masaaki, Iwaki, Motohide, Takahashi, Akihiro, Ginnaga   +9 more
openaire   +2 more sources

Evaluation of botulinum antitoxin, supportive therapy, and artificial respiration in monkeys with experimental botulism

Clinical Pharmacology & Therapeutics, 1968
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
F W, Oberst, J W, Crook, P, Cresthull, M J, House   +3 more
openaire   +2 more sources

Development of an Avian Antitoxin to Type A Botulinum Neurotoxin

1993
Most commercially available antitoxins and antivenoms are raised in horses and purified by bulk fractionation techniques. These preparations frequently elicit deleterious side effects that compromise their efficacy and the treatment of intoxication or envenomation.
B. S. Thalley, M. B. van Boldrik, S. B. Carroll, W. Tepp, B. R. DasGupta, D. C. Stafford   +5 more
openaire   +1 more source

In vitro assays for botulinum toxin and antitoxins.

Developments in biological standardization, 1987
Clostridium botulinum produces several powerful neuroparalytic toxins which, although rare in food-poisoning instances, are generally fatal. A considerable amount of effort has therefore been made by the food industry to ensure that food treatment processes adequate to prevent growth and toxin production by Cl. botulinum.
C, Shone, N, Appleton, P, Wilton-Smith, P, Hambleton, N, Modi, S, Gatley, J, Melling   +6 more
openaire   +1 more source